The Oncology Institute, Inc. (TOIIW) Aandelenanalyse

Bedrijfsoverzicht

The Oncology Institute, Inc. is an oncology entity that delivers a comprehensive array of oncology services across the United States through its specialized operational segments. Although specific sector and industry classifications are not currently disclosed in the available data, the company functions within the healthcare landscape by providing physician services, in-house infusion, and in-house specialty pharmacy solutions. The company employs a workforce of 641 individuals to support its service delivery model across its three primary business units: Specialty Pharmacy, Patient Services, and Clinical Trials & Other. While precise market capitalization data is unavailable, the company reported trailing twelve-month revenue of $502.73M, which, combined with its employee base, indicates a significant operational scale within the specialized oncology service market.

Financiële gezondheid

The company generated total revenue of $502.73M over the trailing twelve months, yet this revenue stream resulted in a net income loss of $50,305,000, highlighting a substantial gap between top-line growth and bottom-line profitability. This discrepancy suggests a cost structure where expenses significantly outweigh profits, further evidenced by an EBITDA figure of $-29,139,000 which reflects ongoing operational challenges in converting revenue into cash earnings. Free cash flow stands at $-11,004,375, indicating that the company is currently burning cash rather than generating liquidity, which limits its immediate financial flexibility for capital expenditures or share buybacks. The gross margin is reported at 15.2%, suggesting that after direct costs of services, the company retains a modest portion of revenue before overhead. Operating margin is negative at -4.9%, while profit margin is even lower at -12.1%, demonstrating that administrative and selling expenses are eroding profitability more aggressively than the core business operations. On the balance sheet, the company holds $33.56M in cash against $103.75M in debt, creating a negative net cash position that requires careful debt management. The debt-to-equity ratio is not explicitly provided, but the disparity between assets and liabilities is clear given the negative price to book ratio of -0.20. Liquidity is supported by a current ratio of 1.59, indicating that current assets are 1.59 times greater than current liabilities, which provides a buffer for short-term obligations despite the cash burn. Return on Equity is not available for calculation, but Return on Assets stands at -13.4%, revealing that the company's assets are generating negative returns on the capital invested.

Waarderingsbeoordeling

Trailing P/E and forward P/E ratios are not applicable due to the company's lack of net income, which prevents standard earnings-based valuation multiples from being calculated. In the absence of a positive earnings base, the price to book ratio is the primary available metric, standing at -0.20, which indicates the market prices the company at 20% below its book value per share. This negative premium reflects the market's assessment of the company's current financial distress and the challenges in realizing value from its asset base. Price to sales and EV/EBITDA metrics are also unavailable or not applicable in standard terms given the negative earnings and cash flow figures, necessitating an analysis based on asset values and revenue generation instead. The stock's price has fluctuated within a 52-week range, hitting a high of $0.05 and a low of $0.03, placing the current trading environment within a narrow band of historical volatility. The beta of the stock is 0.20, which signifies that the share price exhibits significantly lower volatility than the broader market, moving only 20% as much as the market index in response to general market movements.

Growth & Income

Revenue growth year-over-year is robust at 41.6%, demonstrating strong top-line expansion, whereas earnings growth is not applicable due to continued losses, implying that revenue gains have not yet translated into profitability. The company does not pay a dividend, as indicated by the absence of a dividend yield and payout ratio, meaning all available cash is retained to fund operations or reduce debt rather than distributed to shareholders. This reinvestment strategy is typical for growth-stage companies facing profitability hurdles, where capital is directed toward sustaining the 41.6% revenue growth trajectory rather than providing income to investors. The overall profile presents a high-growth revenue stream coupled with significant financial losses and a lack of dividend income, creating a speculative investment case reliant on future operational turnaround.